338840
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166,… Read more
338840 (338840) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.091x
Based on the latest financial reports, 338840 (338840) has a cash flow conversion efficiency ratio of -0.091x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.51 Billion) by net assets (₩16.68 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
338840 - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how 338840's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
338840 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 338840 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Runben Biotechnology Co Ltd Ordinary Shares - Class A
SHG:603193
|
0.042x |
|
Manorama Industries Limited
NSE:MANORAMA
|
0.013x |
|
Circassia Group Plc
OTCGREY:CSSPF
|
0.015x |
|
NIIT LEARNING SYSTEMS LTD
NSE:NIITMTS
|
N/A |
|
Tristel PLC
PINK:TSNLF
|
0.161x |
|
ADVA Optical Networking SE
PINK:ADVOF
|
0.047x |
|
389650
KQ:389650
|
0.000x |
|
Heba Fastighets AB Series B
LSE:0GNV
|
0.010x |
Annual Cash Flow Conversion Efficiency for 338840 (2022–2024)
The table below shows the annual cash flow conversion efficiency of 338840 from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩18.36 Billion | ₩-4.14 Billion | -0.226x | +30.55% |
| 2023-12-31 | ₩23.41 Billion | ₩-7.61 Billion | -0.325x | +60.47% |
| 2022-12-31 | ₩12.29 Billion | ₩-10.10 Billion | -0.822x | -- |